Researchers study digoxin dosing in infants with rare heart condition
NCT ID NCT06613477
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This study looks at how the heart medication digoxin is processed in infants born with single ventricle heart disease. Researchers will collect blood samples during routine care to measure drug levels. The goal is to better understand dosing, but the study does not change the infant's treatment plan. About 20 infants under 6 months old will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANT, PREMATURE, DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27701, United States
Contact Email: •••••@•••••
-
Medical University of South Carolina
NOT_YET_RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
digoxin (Lanoxin)
What this could lead to
If successful, this could lead to more precise digoxin dosing for infants with single ventricle heart disease, potentially improving heart function and reducing side effects.
What could go wrong
This is an early-phase study with only 20 infants, so results may not apply to all patients. The study does not test whether digoxin improves outcomes, only how it is processed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.